The Newcastle upon Tyne Hospitals NHS Foundation Trust

Population 1,800,000
Beds 1,659
Income £858,090k
Comprehensive Surplus (£33,888k)
Operating Surplus £23,725k
EBITDA £64,028k
PPI Cap 1.2%
PPI £4,656k
Public Members 5,739

The Annual Report [1] lists many joint ventures:

The Trust is a stakeholder in a number of spin-offs and commercial ventures, of which the most important is Freeman Clinics Limited, which operates two health centres in partnership with local GPs, one at Ponteland Road, Newcastle, the other at Battle Hill, North Tyneside.

On a 50:50 basis with the University of Pittsburgh Medical Center (UPMC), the Trust is a shareholder in Crossco (1080) Limited, which was set up to promote the sale of the Newcastle eRecord patient records system. The company was dormant and did not trade in 2011/12.

The Trust also holds shares in and is represented on the Boards of NewGene Limited, which markets novel genetic tests to other NHS bodies; Pulse Diagnostics Limited, which is seeking to commercialise an invention for the non-invasive detection of Peripheral Vascular Disease; and Limbs Alive Limited, which is commercialising advanced games software with a therapeutic benefit for children who have suffered a stroke.

The Annual Accounts says that joint ventures represent an asset of £130k.

The trust’s website [2] lists its private patient facilities:

The Lodge – Private Outpatient Consulting Rooms. The Lodge is a dedicated outpatient consulting room facility based at the Royal Victoria Infirmary.

The Park Suite – Private Inpatient suite. The Park Suite is the Trust’s newly opened Private Patient facility at the Royal Victoria Infirmary – purpose built for private patients with the highest standard of comfort and privacy with all the rooms having en–suite facilities.

Please note that unfortunately for clinical reasons not all of our range of procedures are carried out at The Park Suite, and for some operations such as Cardiac and Spinal Surgery you will be admitted to a NHS ward (we try to provide a side room where possible). This is reflected in the fees charged.

The Forward Plan [3] SWOT analysis lists AQP as an opportunity, whereas the Threats part of the SWOT analysis indicates that there is an “overcrowding” of providers in the local health economy:

Overcrowding in the secondary care sector within the local health economy and the consequences that may arise

The trust indicates that they will increase private patient income, one objective of the financial strategy is:

To maximise income through commercial activities to reinvest in NHS care.

The trust also indicates commercial involvement in their research strategy, saying that they will:

Increase commercial trial participation and associated income.

Furthermore:

Working with the Faculty to attract more commercial research income, including scope for a Top 10 research centres consortium

Site Map
Up: Trust profiles


[1] www.monitor-nhsft.gov.uk/sites/all/modules/fckeditor/plugins/ktbrowser/_openTKFile.php?id=13271
[2] www.newcastle-hospitals.org.uk/services/private-patients.aspx
[3] www.monitor-nhsft.gov.uk/sites/all/modules/fckeditor/plugins/ktbrowser/_openTKFile.php?id=11651